Furthermore, combined treatment of γ-tocotrienol with the PPARγ antagonists, GW9662 and T0070907, significantly inhibited growth of MCF-7 and MDA-MB-231 breast cancer cells, and this effect was associated with a corresponding decrease in PPARγ activity and expression. This evidence concerns the gene PPARG and breast carcinoma.